ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype -WAYNE, Pa., (GLOBE ...
Aclaris reports potential of ATI-2138 as a dual inhibitor for inflammatory diseases, with promising preclinical and clinical trial results. Aclaris Therapeutics, Inc. has announced the publication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results